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Accepted 9 April 2012Brain cells display an amazing ability to respond to several different types of environmental
stimuli and integrate this response physiologically. Some of these responses can outlive the
original stimulus by days, weeks or even longer. Long-lasting changes in both physiological
and pathological conditions occurring in response to external stimuli are almost always
mediated by changes in gene expression. To effect these changes, cells have developed an
impressive repertoire of signaling systems designed to modulate the activity of numerous
transcription factors and epigenetic mechanisms affecting the chromatin structure. Since
its initial characterization in the nervous system, NF-κB has shown to respond to multiple
signals and elicit pleiotropic activities suggesting that it may play a pivotal role in integration
of different types of information within the brain. Ample evidence demonstrates that
NF-κB factors are engaged in and necessary for neuronal development and synaptic
plasticity, but they also regulate brain response to environmental noxae. By focusing on
the complexity of NF-κB transcriptional activity in neuronal cell death, it emerged that
the composition of NF-κB active dimers finely tunes the neuronal vulnerability to brain
ischemia. Even though we are only beginning to understand the contribution of distinct
NF-κB family members to the regulation of gene transcription in the brain, an additional
level of regulation of NF-κB activity has emerged as operated by the epigenetic mechanisms
modulating histone acetylation. We will discuss NF-κB and epigenetic mechanisms as
integrative regulators of brain resilience to anoxic stress anduseful drug targets for restoration
of brain function.
This article is part of a Special Issue entitled Brain Integration.
© 2012 Elsevier B.V. All rights reserved.Keywords:
NF‐κB
OGD
Preconditioning
RelA acetylation
Epigenetic
Resveratrolacology, Department of Biomedical Sciences & Biotechnologies, Viale Europa, 11, 25123
zzi).
otein; HAT, histone acetyltransferase; HDAC, histone deacetylase; K310, lysine 310; MCAO,
lear factor kappa B; OGD, oxygen glucose deprivation; SIRT1, sirtuin 1
r B.V. All rights reserved.
l., NF‐κB and epigenetic mechanisms as integrative regulators of brain resilience to
16/j.brainres.2012.04.013
2 B R A I N R E S E A R C H X X ( 2 0 1 2 ) X X X – X X XContents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
2. NF-κB in CNS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
3. NF-κB in neuron survival . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
4. NF-κB and stroke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
5. Epigenetic mechanisms regulate NF-κB activity in brain ischemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
6. Future perspectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Conflict of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 01. Introduction
Epigenetics is a rapidly expanding field that focuses on stable
and heritable changes in gene expression that are not
accompanied by changes in DNA sequence. Different defini-
tions of epigenetics have been claimed since Waddington
(1942) first coined the term in the 1940s. Nowadays the most
agreed is the following: the structural adaptation of chromo-
somal regions so as to register signals or perpetuate altered
activity states (Bird, 2007). Epigenetic machinery represents
the effector of stable chromatin modifications during cell
division and development, but it also represents the molec-
ular interface mediating gene–environmental interactions
during critical periods throughout the lifecycle (Fagiolini
et al., 2009; Mehler, 2008). Several mechanisms contribute to
the epigenetic regulation of transcriptional activity, such as
DNA methylation (Laird, 2010), post translational modifica-
tions of histone proteins (Heintzman et al., 2009; Wang et al.,
2008), nucleosome repositioning (Kerppola, 2009), expression
of microRNA and non-coding RNAs (Guttman et al., 2009), and
RNA and DNA editing (Mattick, 2009). DNA and histone
modifications can affect transcription in two different ways.
One is through direct alteration of the chromatin packing
to open or close the DNA polymer and control the access of
DNA-binding proteins such as transcription factors. The other
is through alteration of the nucleosome surface to promote
the association of chromatin binding proteins. It explains why
the differentiated cells in a multicellular organism express
only the genes that are necessary for their own activity
(Berger, 2007) and require mutually reinforcing mechanisms
permitting heritable patterns of gene silencing. Mutations in
genes that affect global epigenetic profiles can give rise to
human diseases (Egger et al., 2004). Recent studies have shed
some light on the relationship between epigenetic alterations
and central nervous system (CNS) disorders (De Sario, 2009;
Urdinguio et al., 2009). Although CNS disorders are character-
ized by epigenetic persistence of an altered chromatin state,
it has emerged that most of the histone modifications are
reversible and can be affected by drugs. Thus, a comprehen-
sive understanding of epigenetic mechanisms, their interac-
tions and alterations in health and disease, has become a
priority in biomedical research.
Neurodegenerative disorders create a tremendous burden
on aging societies, due to their destructive nature, the number
of affected individuals and the health care costs. Developing
innovative therapies for neurodegenerative diseases representsPlease cite this article as: Sarnico, I., et al., NF‐κB and epigenetic
anoxic stress, Brain Res. (2012), doi:10.1016/j.brainres.2012.04.013a great chance to reduce disability, improve the quality of life
and decrease national direct and indirect health-related costs.
For this purpose, investigations on factors affecting neuronal
vulnerability or resilience are considered a top priority of
translational research in neurology nowadays. Among the
age-related neurodegenerative disorders, the post-ischemic
brain injury represents the first cause of long term disability
and the second cause of death in the western world, but at the
present time there is a stunning lack of efficacious treatments.
Understanding the cellular and molecular machineries un-
derlying the pathogenesis of such a devastating disorder will
facilitate the development of strategies to limit brain damage
and facilitate the recovery. The cellular and molecular mecha-
nisms activated in brain ischemia are complex and not
completely clarified. The involvement of the nuclear factor
kappa B (NF-κB) pathway in triggering inflammatory and
neurodegenerative processes has been well established, but
the tools to finely dissect detrimental from beneficial NF-κB
activation are still limited (Mattson and Meffert, 2006; Ridder
and Schwaninger, 2009).2. NF-κB in CNS
In CNS NF-κB acts as regulator of growth, differentiation, and
adaptive responses to extracellular signals (Kaltschmidt et al.,
1993; O′Neill and Kaltschmidt, 1997;West et al., 2002). However,
NF-κB activation is also involved in the pathophysiology
of neurological diseases associated with neurodegeneration
(Clemens et al., 1997; O′Neill and Kaltschmidt, 1997; Schneider
et al., 1999), where a dual role of NF-κB as regulator of apoptosis
has been demonstrated and widely discussed (Grilli et al., 1996;
Kaltschmidt et al., 1999; Mattson and Camandola, 2001; Pizzi
and Spano, 2006; Qin et al., 1999; Yu et al., 1999).
Several studies focused on the expression and regulation
of NF-κB transcription factor in the nervous system as a
pleiotropic regulator of target genes controlling physiological
function. Different members of the NF-κB family have been
identified in mammalian cells, these include p65 (RelA), RelB,
c-Rel, p50/p105 (NF-κB1), and p52/p100 (NF-κB2). Among the
members of the NF-κB family, only RelA, c-Rel and RelB are able
to activate the transcription of target genes. The transcriptional
capacity of p50 and p52, which are initially synthesized as
large precursors called p105 and p100, depends on dimerization
with RelA, c-Rel or RelB (Dejardin, 2006; Siebenlist et al., 1994). In
the absence of stimuli, these factors are present as homo- andmechanisms as integrative regulators of brain resilience to
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exhibit a conserved 300-aminoacid Rel homology domain
(RHD), responsible for interaction with IκBs, dimerization
and binding to DNA. In stimulated cells, activation of NF-κB
can occur through either a canonical or alternative pathway
(Bonizzi and Karin, 2004). The canonical pathway involves
signal-dependent activation of IκB kinase (IKK) complex,
composed of two catalytic subunits, IKK1/α and IKK2/β, and a
regulatory subunit NF-κB essential modulator (NEMO)/IKKγ.
Upon stimulation, IKK2 phosphorylates two N-terminal serines
within the IκBs, leading to its proteosomal degradation and
subsequent NF-κB release.
In the alternative pathway, IKKα is activated and mediates
the phosphorylation of p100 followed by its ubiquitination and
processing to p52 (Karin and Ben-Neriah, 2000). The subse-
quent translocation of NF-κB dimers to the nucleus, leads to
their association with coactivators to form the transcription
complex, which binds to κB sites with consensus sequence
GGGRNNYYCC (N=any base, R=purine, Y=pyrimidine) and the
transcription of target genes can be activated. NF-κB signaling
can be switched off through multiple mechanisms including
IκBα protein new synthesis, a NF-κB-target gene able to bind
nuclear NF-κB and shuttle it to the cytosol.
Over the last years new studies have emerged, suggesting
that post-translational modifications of NF-κB, such as phos-
phorylation and acetylation,may represent an additional level
of regulation (Hoffmann et al., 2003). The final transcriptional
response is not just defined by the liberation of NF-κB from
IκB but, in addition, reflects the integration of dynamic post-
translational modifications of NF-κB itself as well as the
histones that surround NF-κB target genes (Chen and Greene,
2004).3. NF-κB in neuron survival
Over the past decades the role of NF-κB has been intensely
debated, due to the contradictory evidence that emerged
from a wide investigation. Many studies supported the anti-
apoptotic effects of NF-κB (Koulich et al., 2001; Lezoualc′h et
al., 1998; Maggirwar et al., 1998; Middleton et al., 2000) leading
to neuronal resistance to excitotoxicity- (Yu et al., 1999) or Aβ-
induced apoptosis (Kaltschmidt et al., 1999) in cultured
neurons. Other studies demonstrated that the activation of
NF-κB triggers neuronal degeneration after cerebral ischemia
(Clemens et al., 1997; Schneider et al., 1999), mediates the
glutamate-activated cell death program during excitotoxic
insults to central neurons (Goffi et al., 2005; Grilli and Memo,
1999; Grilli et al., 1996; Pizzi et al., 2005a; Qin et al., 1999;
Sarnico et al., 2008a) and the Aβ-mediated apoptosis (Valerio
et al., 2006). In order to elucidate these incongruous data,
we provided the first direct evidence about the dual role for
NF-κB proteins as either cell death- or cell survival-promoting
factors. In both cultured rat cerebellar granule cells andmouse
hippocampal slices, we examined NF-κB activation induced
by two opposing modulators of cell viability: interleukin-1β
(IL-1β), which promoted neuron survival by activating the p50,
RelA, and c-Rel proteins, and glutamate which elicited toxicity
and concomitantly activated the p50 and RelA subunits of
NF-κB. We hypothesized that the balance between cell deathPlease cite this article as: Sarnico, I., et al., NF‐κB and epigenetic
anoxic stress, Brain Res. (2012), doi:10.1016/j.brainres.2012.04.013and survival in response to external stimulimight be regulated
by activation of distinct NF-κB proteins. By using antisense-
oligonucleotides, we found that the RelA knock-down reduced
glutamate toxicity while the c-Rel knock-down depressed the
neuroprotective activity of IL-1β against glutamate. Moreover,
the c-Rel antisense made IL-1β exposure per se as toxic as
the glutamate one (Pizzi et al., 2002). Further investigations
confirmed that p50 and RelA subunit activation contributes to
the apoptotic program in cells exposed to the β-amyloid
peptide (Akama et al., 1998; Pizzi et al., 2005b; Valerio et al.,
2006). In addition, the c-Rel-containing dimers p50/c-Rel
and RelA/c-Rel are involved in neuroprotective effects elicited
by S100B (Kögel et al., 2004), agonists at the metabotropic
glutamate type 5 (mGlu5) receptors (Pizzi et al., 2005b; Sarnico
et al., 2008b) or leptin (Valerio et al., 2009). Neuroprotection
elicited by c-Rel against β-amyloid toxicity was associated with
the expression of the antiapoptotic proteins B-cell lymphoma-
extra large (Bcl-xL) and manganese superoxide dismutase
(MnSOD) (Pizzi et al., 2005b) (Fig. 1A).4. NF-κB and stroke
Extracellular stimuli that activate the NF-κB pathway include
proinflammatory cytokines, physical and oxidative stress,
apoptotic mediators, elevation of intracellular calcium levels
and excitotoxicity (Barnes and Karin, 1997; Ghosh et al., 1998;
Siebenlist et al., 1994), many of which have been implicated
in pathogenesis of post-ischemic injury (Crack et al., 2006;
Herrmann et al., 2005; Nurmi et al., 2004; Schneider et al.,
1999). In severe ischemia, NF-κB contributes to neuronal
cell death program leading to irreversible brain damage. In
contrast, in sublethal ischemia NF-κB contributes to the
preconditioning effect by dampening its own subsequent full
activation through the activation of IκBα transcription (Blondeau
et al., 2001; Ridder and Schwaninger, 2009).
We afforded the dual effect of NF-κB activation in pre-
conditioning and lethal ischemia using neuronal cells exposed
to oxygen glucose deprivation (OGD) and mice subjected to
middle cerebral artery occlusion (MCAO) (Lanzillotta et al.,
2010; Pizzi et al., 2009). After exposure to lethal ischemia,
neuronal nuclei displayed a high level of p50/RelA activation
(Crack et al., 2006; Inta et al., 2006) and decreased level of c-Rel-
containing dimers (Sarnico et al., 2009a, 2009b). Accordingly,
mice deficient in p50 or RelA, but not mice deficient in c-Rel
subunit, showed a reduced infarct sizewhen exposed toMCAO
(Inta et al., 2006; Schneider et al., 1999). The specific activation
of NF-κBwas associatedwith an unbalanced expression of NF-
κB target genes belonging to the Bcl-2 family regulators of
apoptosis. Mostly, the pro-apoptotic members Bim and Noxa,
under the transcriptional control of RelA, increased in cortical
neurons of ischemic mice (Inta et al., 2006), while the anti-
apoptotic member Bcl-xL decreased (Cao et al., 2002; Sarnico
et al., 2009a). The overexpression of RelA worsened cell death.
The overexpression of c-Rel prevented the neuronal loss after
ischemic injury by increasing the transcription of Bcl-xL gene
(Pizzi et al., 2009; Sarnico et al., 2009a). Furthermore,
the adipocyte-derived hormone leptin, by activating c-Rel-
containing dimers c-Rel/p50 and c-Rel/RelA, significantly
increased Bcl-xL expression and reduced the infarct volumemechanisms as integrative regulators of brain resilience to
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Fig. 1 – NF-κB dimer composition and post-transcriptional modifications of NF-κB subunits represent diverse levels of
regulation of NF-κB activity in response to environmental stimuli affecting neuron survival. A). The c-Rel-containing dimers,
p50/c-Rel and RelA/c-Rel, mediate neuroprotective effects elicited by interleukin-1β, mGlu5 receptor agonists, S100B and leptin
through the induction of anti-apoptotic gene expression. Activation of p50/RelA dimer mediates the neurotoxic effects elicited
by NMDA, β-amyloid and lethal ischemia through the transcription of pro-apoptotic genes. B). The p50/RelA dimer is rapidly
induced either by prolonged lethal ischemia or by brief, preconditioning ischemia. However, the acetylation state of nuclear
RelA is different in the two conditions. In preconditioning ischemia, RelA is highly acetylated on its lysine residues with the
exclusion of the K310. After prolonged ischemia, the RelA undergoes a general lysine deacetylation but its acetylation on K310
increases. CBP–RelA interaction is higher in lethal ischemia than in preconditioning ischemia. HDAC inhibitors in association
with resveratrol couldmaintain the NF-κB activation and switch the RelA acetylation toward its “preconditioning profile”, thus
producing neuroprotection. CRE, cAMP responsive element; CREB, CRE binding protein; CBP, p300/CREB-binding protein; C/EBP,
CCAAT-enhancer-binding protein; p/CAF, p300/CBP-associated factor; HAT, histone acetyltransferase; HDAC, histone
deacetylase; HDACi, HDAC inhibitors; NF-κB, nuclear factor kappa B; NRF, NF-κB repressing factor; SIRT1, sirtuin 1.
4 B R A I N R E S E A R C H X X ( 2 0 1 2 ) X X X – X X Xin mice exposed to permanent MCAO. As a confirmation of
the pivotal role of c-Rel in limiting apoptosis, the protective
effect of leptin in brain ischemia was suppressed in c-Rel
deficient mice (Valerio et al., 2009).
All these data strongly supported the view that in lethal
ischemia the activation of p50⁄RelA dimer and the concom-
itant deactivation of c-Rel-containing dimers are key eventsPlease cite this article as: Sarnico, I., et al., NF‐κB and epigenetic
anoxic stress, Brain Res. (2012), doi:10.1016/j.brainres.2012.04.013in the pathogenesis of post-ischemic brain injury. What
remained to be clarified was the mechanism of neuroprotec-
tion elicited by NF-κB in preconditioning ischemia (Blondeau
et al., 2001). Indeed, a similar pattern of p50/RelA without
c-Rel activation was found in brains of mice exposed to
preconditioning or lethal ischemia (Lanzillotta et al., 2010).
This suggested that the nuclear translocation of p50/RelAmechanisms as integrative regulators of brain resilience to
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during ischemia and that mechanisms shaping the p50/RelA
transcriptional activity could be responsible for a dual effect
of NF-κB. In line with this view, studies in tumor cells had
showed that the RelA subunit acts as an inducer of anti-
apoptotic gene expression, but under certain circumstances
it is able to repress the same target genes (Campbell and
Perkins, 2004; Rocha et al., 2005). A possible solution to the
Doctor Jekyll and Mister Hyde performance of p50/RelA is to
be sought in epigenetics.5. Epigenetic mechanisms regulate NF-κB
activity in brain ischemia
Recent findings are delineating that acetylation of histone and
non-histone proteins is involved directly and indirectly in
controlling the duration, strength and specificity of the NF-κB-
activity at multiple levels (Aguilera et al., 2004; Viatour et al.,
2003; Yamamoto et al., 2003). Acetylation and deacetylation
events, in combination with other post-translational protein
modifications, generate ‘NF-κB-signaling code’ and regulate NF-
κB-dependent gene transcription in an inducer- and promoter-
dependent manner. Indeed, the intricate involvement of
histone acetyltransferases (HAT) and histone deacetylases
(HDAC) modulates both the NF-κB-signaling pathway and the
transactivation of NF-κB-dependent genes (Chen et al., 2001,
2005; Furia et al., 2002; Hoberg et al., 2006; Kiernan et al., 2003;
Mittal et al., 2006; Yeung et al., 2004).
Acetylation of RelA is a dynamic process where the
acetylation status of specific lysine residues affects both the
DNA-binding ability and transcriptional activity of the protein
(Chen et al., 2002; Kiernan et al., 2003).
Once in the nucleus, RelA subunit is phosphorylated
at distinct serine residues and then activates transcription
by interacting with HAT co-activators, including p300/CREB
binding protein (p300/CBP), the steroid receptor-coactivator-1,
and the p300/CBP-associated factor (p/CAF) (Gerritsen et
al., 1997; Perkins et al., 1997; Zhong et al., 1998). Besides
acetylating the N-terminal tails of core histones surrounding
NF-κB-regulated genes, HATs are directly responsible for
RelA acetylation. This effect is believed to facilitate an ‘open
chromatin’ configuration, allowing transcription (Mayo et al.,
2003). Site-specific acetylation of NF-κB RelA at multiple
lysines (K122, 123, 218, 221, and 310) can differently affect
the interaction with IκBα, the DNA-binding or the transcrip-
tional activity of the factor (Chen and Greene, 2004; Kiernan
et al., 2003).
In addition to co-activators, RelA also recruits co-repressor
complexes, endowed with deacetylase activity. Members of
the class I HDAC (HDAC1, HDAC2, and HDAC3) deacetylate
RelA, resulting in increased IκBα association and loss of
transactivation potential of the factor (Ashburner et al., 2001;
Chen and Greene, 2004; Zhong et al., 2002). Sirtuins, homologs
of the yeast SIR2 family, belong to the atypical class III HDACs
(Frye, 2000) and require nicotinamide adenosine dinucleotide
(NAD+) as a cofactor (Buck et al., 2004). While the members of
class I HDACs are the most responsible for general RelA
deacetylation, sirtuin 1 (SIRT1) selectively deacetylates RelA at
K310 (Yeung et al., 2004).Please cite this article as: Sarnico, I., et al., NF‐κB and epigenetic
anoxic stress, Brain Res. (2012), doi:10.1016/j.brainres.2012.04.013Recently, we tested whether epigenetic mechanisms af-
fecting the acetylation state of histones and RelA might
discriminate between preconditioning and neurotoxic activa-
tion of NF-κB during ischemia. In ischemic cortices of mice
subjected to MCAO, as well as in cortical neurons exposed
to lethal OGD, activated RelA displayed a high level of K310
acetylation in spite of a reduced level of total lysine acetyla-
tion. Conversely, RelA activated during preconditioning ische-
mia conserved its general acetylation, but showed a specific
deacetylation on the K310 residue. CBP strongly interacted
with RelA during lethal ischemia, while the interaction was
reduced in preconditioning ischemia, indicating a role for this
HAT moiety in the process of site-specific acetylation on RelA
K310 (Fig. 1B). Molecular manipulation of RelA acetylation
through expression of an acetylation resistant RelA-K310-R
mutant construct, or the pharmacological deacetylation of
RelA on K310 by the SIRT1 activator resveratrol, reduced
Bim promoter activity during OGD and reduced cell death
(Lanzillotta et al., 2010).
These results give evidence of the role of RelA acetylation
in driving cell decision to either fight or capitulate to ischemic
challenge. The acetylation of RelA in K310 dictates NF-κB-
dependent pro-apoptotic and pro-inflammatory responses
(Chen et al., 2002, 2005) and may represent a suitable target
to dissect pathological from neuroprotective activation of
NF-κB in brain ischemia.6. Future perspectives
The identification of molecular mechanisms shaping activa-
tion and transcriptional activity of diverse NF-κB dimers in the
brain will unravel new potential targets to treat neurological
diseases associated with inflammation and apoptotic cell
death. The derangement of RelA acetylation, in particular,
may represent a new drugable target to design efficient
therapies aimed at limiting brain damage while preserving
the integrative activity of NF-κB in regulating immune and
cognitive functions. The goal of this therapeutic approach
should be to increase the general lysine acetylation of RelA
and achieve its specific deacetylation at K310.
RelA acetylation can be modified by using HDAC inhibitors
that have already proved to be effective in attenuating
neurological deficits and neuronal loss in various animal
models of brain ischemia (Kim et al., 2007; Ren et al., 2004),
Huntington's disease (Ferrante et al., 2003; Gardian et al., 2005;
Hockly et al., 2003), spinal muscular atrophy (Chang et al.,
2001), amyotrophic lateral sclerosis (Corcoran et al., 2004; Petri
et al., 2006; Ryu et al., 2005), and experimental autoimmune
encephalomyelitis (Camelo et al., 2005). Among HDAC in-
hibitors, suberoylanilide hydroxamic acid (SAHA), trichostatin
A (TSA) and MS-275 (entinostat) are effective in inhibiting
the HDAC1, HDAC2 and HDAC3 isoforms (Blackwell et al.,
2008) that are the most involved in RelA deacetylation
(Ashburner et al., 2001; Chen and Greene, 2004; Zhong et al.,
2002). On the other side, the specific deacetylation of RelA at
the K310 residue could be achieved by using the SIRT1
activator resveratrol which reduces pro-apoptotic transcrip-
tion and rescues neuronal cells from apoptosis (Lanzillotta
et al., 2010). The association of such drugs endowed withmechanisms as integrative regulators of brain resilience to
6 B R A I N R E S E A R C H X X ( 2 0 1 2 ) X X X – X X Xdifferent mechanisms of action and targeting both histones
and aberrant RelA acetylation, might unravel a new thera-
peutic approach to treat neurodegenerative disorders by
preserving neural integrative functions and sustain brain
restoration.
The epigenetic machinery that regulates acetylation of
histones, transcription factors and DNA is intimately involved
in synaptic plasticity, learning and memory and age-related
neurodegenerative disorders. Therapies, aimed to correct
the dysfunction in chromatin plasticity and the activity of
NF-κB transcription factor may represent a new challenge
for effective “disease modifying” strategies.Conflict of interest
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